278 related articles for article (PubMed ID: 10980846)
21. Non-lipid-related effects of statins.
Bellosta S; Ferri N; Bernini F; Paoletti R; Corsini A
Ann Med; 2000 Apr; 32(3):164-76. PubMed ID: 10821323
[TBL] [Abstract][Full Text] [Related]
22. Adjunctive interventions in myocardial infarction: the role of statin therapy.
Jones PH; Farmer JA
Curr Atheroscler Rep; 2008 Apr; 10(2):142-8. PubMed ID: 18417069
[TBL] [Abstract][Full Text] [Related]
23. [Anti-atherosclerotic actions of HMG-CoA reductase inhibitors].
Gmiński J; Wojakowski W
Przegl Lek; 1997; 54(11):782-7. PubMed ID: 9501689
[TBL] [Abstract][Full Text] [Related]
24. Preservation of endothelial function by the HMG-CoA reductase inhibitor fluvastatin through its lipid-lowering independent antioxidant properties in atherosclerotic rabbits.
Mitani H; Egashira K; Ohashi N; Yoshikawa M; Niwa S; Nonomura K; Nakashima A; Kimura M
Pharmacology; 2003 Jul; 68(3):121-30. PubMed ID: 12784083
[TBL] [Abstract][Full Text] [Related]
25. Cholesterol lowering and endothelial function.
Vogel RA
Am J Med; 1999 Nov; 107(5):479-87. PubMed ID: 10569303
[TBL] [Abstract][Full Text] [Related]
26. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells.
Dichtl W; Dulak J; Frick M; Alber HF; Schwarzacher SP; Ares MP; Nilsson J; Pachinger O; Weidinger F
Arterioscler Thromb Vasc Biol; 2003 Jan; 23(1):58-63. PubMed ID: 12524225
[TBL] [Abstract][Full Text] [Related]
27. Effects of statins on the vasculature: Implications for aggressive lipid management in the cardiovascular metabolic syndrome.
Sowers JR
Am J Cardiol; 2003 Feb; 91(4A):14B-22B. PubMed ID: 12615294
[TBL] [Abstract][Full Text] [Related]
28. Statins attenuate the development of atherosclerosis and endothelial dysfunction induced by exposure to urban particulate matter (PM10).
Miyata R; Hiraiwa K; Cheng JC; Bai N; Vincent R; Francis GA; Sin DD; Van Eeden SF
Toxicol Appl Pharmacol; 2013 Oct; 272(1):1-11. PubMed ID: 23756175
[TBL] [Abstract][Full Text] [Related]
29. Comparison of endothelial pleiotropic actions of angiotensin converting enzyme inhibitors and statins.
Gryglewski RJ; Uracz W; Swies J; Chlopicki S; Marcinkiewicz E; Lomnicka M; Madej J
Ann N Y Acad Sci; 2001 Dec; 947():229-45; discussion 245-6. PubMed ID: 11795271
[TBL] [Abstract][Full Text] [Related]
30. Potential role of statins in inflammation and atherosclerosis.
Yoshida M
J Atheroscler Thromb; 2003; 10(3):140-4. PubMed ID: 14564082
[TBL] [Abstract][Full Text] [Related]
31. Effects of statins on inflammation in patients with acute and chronic coronary syndromes.
Kinlay S; Selwyn AP
Am J Cardiol; 2003 Feb; 91(4A):9B-13B. PubMed ID: 12615293
[TBL] [Abstract][Full Text] [Related]
32. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells.
Mulhaupt F; Matter CM; Kwak BR; Pelli G; Veillard NR; Burger F; Graber P; Lüscher TF; Mach F
Cardiovasc Res; 2003 Sep; 59(3):755-66. PubMed ID: 14499877
[TBL] [Abstract][Full Text] [Related]
33. Direct effects of statins on cells primarily involved in atherosclerosis.
Chen H; Ikeda U; Shimpo M; Shimada K
Hypertens Res; 2000 Mar; 23(2):187-92. PubMed ID: 10770267
[TBL] [Abstract][Full Text] [Related]
34. Statins and blood coagulation.
Undas A; Brummel-Ziedins KE; Mann KG
Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):287-94. PubMed ID: 15569822
[TBL] [Abstract][Full Text] [Related]
35. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability.
Koh KK
Cardiovasc Res; 2000 Sep; 47(4):648-57. PubMed ID: 10974215
[TBL] [Abstract][Full Text] [Related]
36. Antiinflammatory and immunomodulatory properties of statins.
Shovman O; Levy Y; Gilburd B; Shoenfeld Y
Immunol Res; 2002; 25(3):271-85. PubMed ID: 12018465
[TBL] [Abstract][Full Text] [Related]
37. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.
Rosenson RS; Tangney CC
JAMA; 1998 May; 279(20):1643-50. PubMed ID: 9613915
[TBL] [Abstract][Full Text] [Related]
38. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease.
Lefer AM; Scalia R; Lefer DJ
Cardiovasc Res; 2001 Feb; 49(2):281-7. PubMed ID: 11164838
[No Abstract] [Full Text] [Related]
39. [Statins and endothelial dysfunction].
Filip-Ciubotaru FM; Manciuc C; Foia L
Rev Med Chir Soc Med Nat Iasi; 2009; 113(4):975-83. PubMed ID: 20191862
[TBL] [Abstract][Full Text] [Related]
40. The expanding role of HMG-CoA reductase inhibitors (statins) in the prevention and treatment of ischemic heart disease.
Chilton R; O'Rourke RA
Curr Probl Cardiol; 2001 Dec; 26(12):734-64. PubMed ID: 11743453
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
